GlassScriptPhysician profile
Ahmed Sherif
NPI 1750492096
$10,320.76
in general payments reported to CMS, 2019-2025
29 companies · $3,693 in 2025
The $3,693 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,250 · 2020: $748 · 2021: $474 · 2022: $1,083 · 2023: $935 · 2024: $1,137 · 2025: $3,693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,421 · Food and Beverage: $2,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,421.30 |
| Food and Beverage | $2,344.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $3,629.80 | 2024-2025 | Disposable Distal Attachment, Olympus, Single Use Electrosurgical Knife Kd-655 |
| Boston Scientific Corporation | $2,251.64 | 2019-2024 | Exalt Model D, Watchman Flx |
| Abbvie INC. | $1,754.50 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Olympus America INC. | $564.55 | 2019-2024 | Endoclot Phs, Hanarostent Esophagus Tts(Ccc), Visiglide |
| Apollo Endosurgery US INC | $364.21 | 2022 | |
| Ambu INC. | $235.63 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.51 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $143.21 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.50 | 2019-2022 | |
| Celgene Corporation | $118.56 | 2022-2023 | Zeposia |
| Cook Medical LLC | $115.70 | 2023 | Hemospray |
| Genzyme Corporation | $107.95 | 2025 | |
| Janssen Scientific Affairs, LLC | $103.10 | 2020 | |
| Ethicon US, LLC | $99.27 | 2019 | |
| Lilly USA, LLC | $89.43 | 2024-2025 | Omvoh, Jardiance, Zepbound |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Steris Corporation | $79.52 | 2019 | |
| Qol Medical, LLC | $59.01 | 2024-2025 | Sucraid, Sucraid |
| Novo Nordisk INC | $57.90 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $55.49 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $53.15 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $33.00 | 2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $29.39 | 2024-2025 | Voquezna |
| Nevro Corp. | $22.61 | 2023 | Senza |
| Merck Sharp & Dohme LLC | $19.79 | 2019 | |
| Endogastric Solutions, INC | $19.56 | 2020 | |
| Janssen Biotech, INC. | $18.09 | 2020 | |
| Biogen, INC. | $16.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.69 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Sherif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.